280 related articles for article (PubMed ID: 23032658)
1. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
Fung L
Ann Pharmacother; 2012 Oct; 46(10):e26. PubMed ID: 23032658
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Pharmacotherapy; 1998; 18(5):1069-74. PubMed ID: 9758317
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
Kitzis MD; Goldstein FW
Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
[TBL] [Abstract][Full Text] [Related]
5. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics.
Chua K; Howden BP
Curr Opin Infect Dis; 2009 Dec; 22(6):525-34. PubMed ID: 19738465
[TBL] [Abstract][Full Text] [Related]
6. Comparison of continuous infusion versus intermittent infusion of vancomycin in patients with methicillin-resistant Staphylococcus aureus.
Jaruratanasirikul S; Julamanee J; Sudsai T; Saengsuwan P; Jullangkoon M; Ingviya N; Jarumanokul R
J Med Assoc Thai; 2010 Feb; 93(2):172-6. PubMed ID: 20301996
[TBL] [Abstract][Full Text] [Related]
7. Review of continuous-infusion vancomycin.
DiMondi VP; Rafferty K
Ann Pharmacother; 2013 Feb; 47(2):219-27. PubMed ID: 23386074
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections.
Verrall AJ; Llorin R; Tam VH; Lye DC; Sulaiman Z; Zhong L; Archuleta S; Fisher DA
J Antimicrob Chemother; 2012 Dec; 67(12):2970-3. PubMed ID: 22915464
[TBL] [Abstract][Full Text] [Related]
9. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
10. Aerosolized vancomycin for the treatment of MRSA after lung transplantation.
Hayes D; Murphy BS; Mullett TW; Feola DJ
Respirology; 2010 Jan; 15(1):184-6. PubMed ID: 19895389
[TBL] [Abstract][Full Text] [Related]
11. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency.
Pai MP; Mercier RC; Allen SE
Ann Pharmacother; 2006 Mar; 40(3):553-8. PubMed ID: 16507618
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
[TBL] [Abstract][Full Text] [Related]
13. Continuous vancomycin in a pediatric cystic fibrosis patient.
McKinzie CJ; Esther CR; Vece TJ
Pediatr Pulmonol; 2018 Jan; 53(1):E4-E5. PubMed ID: 29193836
[TBL] [Abstract][Full Text] [Related]
14. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.
Kullar R; Davis SL; Taylor TN; Kaye KS; Rybak MJ
Pharmacotherapy; 2012 Mar; 32(3):195-201. PubMed ID: 22392452
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K; Conway SP; Denton M
J Cyst Fibros; 2005 Mar; 4(1):49-52. PubMed ID: 15752681
[TBL] [Abstract][Full Text] [Related]
16. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol.
Solís A; Brown D; Hughes J; Van Saene HK; Heaf DP
Pediatr Pulmonol; 2003 Sep; 36(3):189-95. PubMed ID: 12910579
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin dosing for pneumonia in critically ill trauma patients.
Patanwala AE; Norris CJ; Nix DE; Kopp BJ; Erstad BL
J Trauma; 2009 Oct; 67(4):802-4. PubMed ID: 19820588
[TBL] [Abstract][Full Text] [Related]
18. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
[TBL] [Abstract][Full Text] [Related]
19. Estimation of safe and effective dose of vancomycin in MRSA-infected patients using serum cystatin C concentrations.
Chen YC; Feng JF; Li B; Zhang L; Yang YW
Int J Clin Pharmacol Ther; 2013 Mar; 51(3):161-9. PubMed ID: 23195915
[TBL] [Abstract][Full Text] [Related]
20. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
